Tafenoquine
Tafenoquine
|
| Systematic (IUPAC) name |
N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)
phenoxy]quinolin-8-yl]pentane-1,4-diamine |
| Clinical data |
| Pregnancy cat. |
? |
| Legal status |
? |
| Identifiers |
| CAS number |
106635-80-7 Y |
| ATC code |
None |
| PubChem |
CID 115358 |
| ChemSpider |
103196 Y |
| UNII |
262P8GS9L9 N |
| ChEMBL |
CHEMBL298470 Y |
| Chemical data |
| Formula |
C24H28F3N3O3 |
| Mol. mass |
463.493 g/mol |
| SMILES |
eMolecules & PubChem |
-
InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3 Y
Key:LBHLFPGPEGDCJG-UHFFFAOYSA-N Y
|
N(what is this?) (verify)
|
Tafenoquine (also called WR 238605 or SB-252263) is an 8-aminoquinoline drug manufactured by GlaxoSmithKline that is currently being investigated as a potential treatment for malaria, as well as for malaria prevention.[1][2]
The main advantage of tafenoquine is that it has a long half-life and therefore does not need to be taken as frequently as primaquine. Like primaquine, tafenoquine causes haemolysis in people with G-6-PD deficiency.[1]
A shorter regimen has also been described as an advantage.[3]
The dose of tafenoquine has not been firmly established, but for the treatment of Plasmodium vivax malaria, a dose of 800 mg over three days has been used.[4]
References
- ^ a b Shanks GD, Oloo AJ, Aleman GM et al. (2001). "A New Primaquine Analogue, Tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria". Clin Infect Dis 33 (12): 1968–74. doi:10.1086/324081. JSTOR 4482936. PMID 11700577.
- ^ Lell B, Faucher JF, Missinou MA et al. (2000). "Malaria chemoprophylaxis with tafenoquine: a randomised study". Lancet 355 (9220): 2041–5. doi:10.1016/S0140-6736(00)02352-7. PMID 10885356.
- ^ Elmes NJ, Nasveld PE, Kitchener SJ, Kocisko DA, Edstein MD (November 2008). "The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific". Transactions of the Royal Society of Tropical Medicine and Hygiene 102 (11): 1095–101. doi:10.1016/j.trstmh.2008.04.024. PMID 18541280. http://linkinghub.elsevier.com/retrieve/pii/S0035-9203(08)00170-3.
- ^ Nasvelda P, Kitchener S. (2005). "Treatment of acute vivax malaria with tafenoquine". Trans R Soc Trop Med Hyg 99 (1): 2–5. doi:10.1016/j.trstmh.2004.01.013. PMID 15550254.
|
|
|
Alveo-
late |
|
|
|
|
|
|
|
|
|
|
|
Individual
agents
|
|
|
|
Combi-
nations
|
Fixed-dose (coformulated) ACTs |
artemether-lumefantrine#
artesunate-amodiaquine ( ASAQ)
artesunate-mefloquine (ASMQ)
dihydroartemisinin-piperaquine
artesunate-pyronaridine
|
|
|
Other combinations
(not co-formulated)
|
artesunate/SP • artesunate/mefloquine •
quinine/tetracycline • quinine/doxycycline • quinine/clindamycin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hetero-
kont |
|
|
|
|
|